Improvement of RG1-VLP vaccine performance in BALB/c mice by substitution of alhydrogel with the next generation polyphosphazene adjuvant PCEP

Current human papillomavirus (HPV) vaccines provide substantial protection against the most common HPV types responsible for oral and anogenital cancers, but many circulating cancer-causing types remain for which vaccine coverage is lacking. In addition, all current HPV vaccines rely on aluminum sal...

Descripció completa

Dades bibliogràfiques

Autors principals:	Sarah M. Valencia, Athina Zacharia, Alexander Marin, Rebecca L. Matthews, Chia-Kuei Wu, Breana Myers, Chelsea Sanders, Simone Difilippantonio, Reinhard Kirnbauer, Richard B. Roden, Ligia A. Pinto, Robert H. Shoemaker, Alexander K. Andrianov, Jason D. Marshall
Format:	Artigo
Idioma:	Inglês
Publicat:	Taylor & Francis Group 2021-08-01
Col·lecció:	Human Vaccines & Immunotherapeutics
Matèries:	human papillomavirus hpv prophylactic vaccine pcep polyphosphazenes adjuvants hpv-l2 neutralizing antibody
Accés en línia:	http://dx.doi.org/10.1080/21645515.2021.1875763
Etiquetes:	Afegir etiqueta Sense etiquetes, Sigues el primer a etiquetar aquest registre!